Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teresa Calimeri

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Nanomedicine : Nanotechnology, Biology, and Medicine|April 2, 2011
Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomesMonica Marra, Giuseppina Salzano, Carlo Leonetti, et al.
British Journal of Haematology|October 21, 2020
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trialAndrés J M Ferreri, Chiara Cattaneo, Arben Lleshi, et al.
Blood|July 24, 2012
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myelomaSimona Blotta, Jana Jakubikova, Teresa Calimeri, et al.
Blood|September 8, 2012
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibitionMichele Cea, Antonia Cagnetta, Mariateresa Fulciniti, et al.
American Journal of Hematology|March 15, 2026
Three-Hour Infusion of Methotrexate at 3 g/m<sup>2</sup> With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B-Cell Lymphomas at Increased CNS RiskAndrés J M Ferreri, Federico Erbella, Piera Angelillo, et al.
British Journal of Haematology|January 31, 2020
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practiceElisabeth Schorb, Christopher P Fox, Benjamin Kasenda, et al.
Journal of Neurology|September 19, 2023
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAF<sup>V600E</sup> mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman diseaseValentina Pieri, Giulia Berzero, Rosina Paterra, et al.
Hemasphere|June 5, 2024
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAndreas J M Ferreri, Gerald Illerhaus, Jeanette K Doorduijn, et al.
Blood|May 24, 2019
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphomaAndrés J M Ferreri, Teresa Calimeri, Gian Marco Conte, et al.
The Lancet. Haematology|February 22, 2017
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trialAndrés J M Ferreri, Marianna Sassone, Francesco Zaja, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Nanomedicine : Nanotechnology, Biology, and Medicine|April 2, 2011
Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomesMonica Marra, Giuseppina Salzano, Carlo Leonetti, et al.
British Journal of Haematology|October 21, 2020
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trialAndrés J M Ferreri, Chiara Cattaneo, Arben Lleshi, et al.
Blood|July 24, 2012
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myelomaSimona Blotta, Jana Jakubikova, Teresa Calimeri, et al.
Blood|September 8, 2012
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibitionMichele Cea, Antonia Cagnetta, Mariateresa Fulciniti, et al.
American Journal of Hematology|March 15, 2026
Three-Hour Infusion of Methotrexate at 3 g/m<sup>2</sup> With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B-Cell Lymphomas at Increased CNS RiskAndrés J M Ferreri, Federico Erbella, Piera Angelillo, et al.
British Journal of Haematology|January 31, 2020
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practiceElisabeth Schorb, Christopher P Fox, Benjamin Kasenda, et al.
Journal of Neurology|September 19, 2023
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAF<sup>V600E</sup> mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman diseaseValentina Pieri, Giulia Berzero, Rosina Paterra, et al.
Hemasphere|June 5, 2024
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAndreas J M Ferreri, Gerald Illerhaus, Jeanette K Doorduijn, et al.
Blood|May 24, 2019
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphomaAndrés J M Ferreri, Teresa Calimeri, Gian Marco Conte, et al.
The Lancet. Haematology|February 22, 2017
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trialAndrés J M Ferreri, Marianna Sassone, Francesco Zaja, et al.
Pageof 6